Clinical Trial Results: A Trial of the Fatty Acid Amide Hydrolase Inhibitor Palmitoylethanolamide in Bipolar Depression [Phase 2]

View source ↗

Summary

Phase 2 trial results for a fatty acid amide hydrolase inhibitor (palmitoylethanolamide) in Bipolar Depression have been completed and results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Bipolar Depression

Drugs mentioned

• Palmitoylethanolamide (palmitoylethanolamide)

Snippet

Sponsor: Rodrigo Machado-Vieira, MD, PhD, MSc | Conditions: Bipolar Depression | Phase 2 | Status: COMPLETED | Results posted: 2026-08-13